Antibody-Mediated Inhibition of CTLA4 Aggravates Atherosclerotic Plaque Inflammation and Progression in Hyperlipidemic Mice
T cell-driven inflammation plays a critical role in the initiation and progression of atherosclerosis. The co-inhibitory protein Cytotoxic T-Lymphocyte Associated protein (CTLA) 4 is an important negative regulator of T cell activation. Here, we studied the effects of the antibody-mediated inhibitio...
Main Authors: | Kikkie Poels, Mandy M. T. van Leent, Myrthe E. Reiche, Pascal J. H. Kusters, Stephan Huveneers, Menno P. J. de Winther, Willem J. M. Mulder, Esther Lutgens, Tom T. P. Seijkens |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2020-08-01
|
Series: | Cells |
Subjects: | |
Online Access: | https://www.mdpi.com/2073-4409/9/9/1987 |
Similar Items
-
E3 Ubiquitin Ligases as Immunotherapeutic Target in Atherosclerotic Cardiovascular Disease
by: Kikkie Poels, et al.
Published: (2020-06-01) -
Adverse Events Following Administration of Anti-CTLA4 Antibody Ipilimumab
by: Amirali Karimi, et al.
Published: (2021-03-01) -
Polymorphisms in the CTLA4 promoter sequence are associated with canine hypoadrenocorticism
by: Alisdair M. Boag, et al.
Published: (2020-03-01) -
Preponderance of CTLA4 Variation Associated With Autosomal Dominant Immune Dysregulation in the MYPPPY Motif
by: Owen M. Siggs, et al.
Published: (2019-07-01) -
Safety profile and pharmacokinetic analyses of the anti-CTLA4 antibody tremelimumab administered as a one hour infusion
by: Ribas Antoni, et al.
Published: (2012-11-01)